HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer acquires supplement brand

This article was originally published in The Tan Sheet

Executive Summary

Bayer HealthCare's Consumer Care division has received regulatory approval to acquire Mission Pharmacal's Citracal calcium supplements, Morristown, N.J.-based Bayer Consumer Care reports Oct. 5. The transaction, which closed Oct. 4, increases the Consumer Care division's market presence in the U.S., Bayer noted. The firm will continue to build upon Citracal's "already strong nutritionals business," which includes leading brands such as One-A-Day, Bayer notes. Primarily sold in North America, the brand generated net sales of $47 mil. in San Antonio-based Mission's fiscal 2007. Bayer announced plans to acquire Citracal in August (1"The Tan Sheet" Sept. 3, 2007, p. 11)...

You may also be interested in...



New Products In Brief

Citracal adds phytosterols: Bayer Consumer Care formulates a line extension of its calcium/vitamin D supplement with natural plant sterols, which may help reduce risk of heart disease. Citracal Calcium Plus Heart Health aims to prevent both osteoporosis-related fractures and heart disease, the most common killer of women, Bayer said Nov. 5. A spokeswoman for the Morristown, N.J., company said the supplement shipped during the summer and is available at food, drug and mass merchandise retailers nationwide. An 80-count bottle sells for the suggested price of $13.99. Bayer acquired the Citracal brand from Mission Pharmacal in 2007 (1"The Tan Sheet" Oct. 8, 2007, In Brief)

Citracal Deal Will Move Bayer Into U.S. Calcium Market, Expand Portfolio

Bayer's Healthcare Consumer Care Division expects to expand its global OTC calcium market offerings through its planned acquisition of Mission Pharmacal's Citracal brand, according to company executives who also say the move will help the firm continue diversifying its nutritional product portfolio

The Growing GLP-1 Therapy Market

Novo Nordisk was not the first biopharmaceutical company to launch a GLP-1 therapy into the market for type 2 diabetes. In fact, Amylin Pharmaceutials’ and Eli Lilly’s Byetta (exenatide) beat Novo’s Victoza (liraglutide) to market by a full five years.  

Topics

UsernamePublicRestriction

Register

RS138386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel